Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00344110
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2006-06-22
Brief Title:
Study Comparing SPP100 Aliskiren 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo and Active-controlled Multicenter Parallel-group Study Comparing SPP100 Aliskiren 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assessing efficacy safety and pharmacokinetics in patients with mild to moderate essential hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None